Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration
NCT06285409Recruiting
- Sponsor
- Mount Sinai Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Trial of carbetocin, oxytocin, ergonovine maleate and carboprost in postpartum hemorrhage (PPH) and uterine atony (5 arms), sponsored by Mount Sinai Hospital. Primary endpoint: Motility index at 4 hours. Started Apr 2024; status: recruiting.
02
Drugs
carbetocinoxytocinergonovine maleatecarboprost
03
Conditions
postpartum hemorrhage (PPH)uterine atony
Beyond the preview
Go deeper on NCT06285409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285409.